8-K: Cidara Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update

Cidara Therapeutics reported its Q1 2025 financial results, highlighted by progress in the Phase 2b NAVIGATE trial for CD388 and key personnel promotions.

Summary

• Cidara Therapeutics reported financial results for the first quarter ended March 31, 2025.
• The company is developing CD388 for the prevention of seasonal influenza.
• The data cutoff for the Phase 2b NAVIGATE trial efficacy analysis was April 30, 2025, with top-line data expected in late June 2025.
• Dosing of 5,041 subjects in the Phase 2b NAVIGATE study was completed in early December 2024.
• The company is discussing changes to the study's statistical analysis plan with the FDA.
• Preclinical data of CD388 was published in Nature Microbiology in March 2025.
• Nicole Davarpanah was promoted to Chief Medical Officer, and Corrina Pavetto to Senior Vice President, Clinical Development in May 2025.
• Cash, cash equivalents, and restricted cash totaled $174.5 million as of March 31, 2025, compared to $196.2 million as of December 31, 2024.
• Collaboration revenue was zero for the three months ended March 31, 2025, compared to $1.0 million for the same period in 2024.
• R&D expenses were $24.6 million for the three months ended March 31, 2025, compared to $5.9 million for the same period in 2024.
• General and administrative (G&A) expenses were $6.2 million for the three months ended March 31, 2025, compared to $3.6 million for the same period in 2024.
• Net loss for the three months ended March 31, 2025 was $23.5 million, compared to a net loss of $10.3 million for the same period in 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company is making progress with its CD388 program and has key personnel promotions, the increased net loss and R&D expenses are concerning. The upcoming data readout from the Phase 2b trial will be a critical factor in determining the future direction of the company.

Positives

• The Phase 2b NAVIGATE trial for CD388 has completed dosing of 5,041 subjects.
• Preclinical data supports CD388's potential as a universal antiviral for influenza.
• Key personnel were promoted to leadership roles, strengthening the company's management team.
• The company is engaging with the FDA to optimize the statistical analysis of the Phase 2b NAVIGATE trial.
• CD388 was granted Fast Track Designation by the FDA in June 2023.
• Cidara received IND clearance for CBO421 in July 2024.

Negatives

• Collaboration revenue decreased to zero due to the termination of the Janssen Collaboration Agreement.
• The net loss increased to $23.5 million for the first quarter of 2025, compared to $10.3 million in 2024.
• R&D expenses increased significantly, impacting the company's profitability.

Risks

• The success of CD388 is dependent on positive results from the Phase 2b NAVIGATE trial and subsequent Phase 3 studies.
• Discussions with the FDA regarding the statistical analysis plan may not result in a favorable outcome.
• Clinical trials are subject to delays and unexpected results.
• The company's financial performance is impacted by increased R&D expenses and the loss of collaboration revenue.
• Regulatory approvals are not guaranteed and are subject to review and potential delays.

Future Outlook

The company anticipates top-line data from the Phase 2b NAVIGATE trial in late June 2025 and expects that data from this trial will enable dose selection for Phase 3 as well as the determination of statistically meaningful comparisons of each dose to the placebo arm of the study.

Management Comments

• Jeffrey Stein, Ph.D., president and chief executive officer of Cidara, stated that the severity of the 2024-2025 flu season has provided an opportunity to discuss changes to the study's statistical analysis plan with the U.S. FDA.
• Management believes CD388 is highly differentiated from vaccines and monoclonal antibodies and can significantly improve upon the protective efficacy against influenza in healthy, high-risk, and immunocompromised patients with a single dose per flu season.

Industry Context

Cidara is developing CD388 as a potential universal prevention for seasonal and pandemic influenza, which addresses a significant unmet need in the market. The company is competing with traditional vaccines and monoclonal antibodies, aiming to offer improved efficacy and convenience with a single-dose regimen.

Comparison to Industry Standards

• Traditional influenza vaccines, such as those from Sanofi and GSK, require annual administration and have varying efficacy rates depending on the circulating strains.
• Monoclonal antibody treatments, like those developed by Regeneron and Roche, are typically used for treatment rather than prevention and may not be effective against all influenza strains.
• CD388 aims to provide a more universal and convenient solution with a single dose per flu season, potentially offering a competitive advantage over existing options.

Management Changes

Stakeholder Impact

• Shareholders are impacted by the company's financial performance and the progress of its clinical programs.
• Employees are affected by personnel changes and the overall success of the company.
• Patients could benefit from the development of CD388 as a potential universal prevention for influenza.
• The company's suppliers and partners are impacted by its R&D activities and financial stability.

Next Steps

• The company expects to report top-line data from the Phase 2b NAVIGATE clinical trial in late June 2025.
• Cidara will continue discussions with the FDA regarding the statistical analysis plan for the Phase 2b NAVIGATE trial.
• The company plans to advance the development of CD388 based on the results of the Phase 2b trial.
• Cidara will continue to develop additional DFCs for oncology.

Key Dates

Keywords

CD388, influenza, Phase 2b NAVIGATE trial, financial results, Cidara Therapeutics, antiviral, clinical trial, FDA, Cloudbreak platform, DFC